logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals receives ethics approval as they begin clinical trials for Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling to announce the company has received ethics approval from a central institutional review board for U.S. study sites for its multinational Phase 2b/3 human study of Ifenprodil for COVID-19.

Moreau explains what that means going forward and he also updated the situation in South Korea and the good news from that country when it comes to the coronavirus.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.235 CAD

CSE:AGN
Market: CSE
Market Cap: $21.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Benchmark Holdings focused on making core business 'commercially profitable'

Benchmark Holdings PLC's (LON:BMK) CEO Trond Williksen and CFO Septima Maguire says they're pleased with what's been achieved with its restructuring programme following the sales of FishVet and Improve International. Williksen says it demonstrates their ability to execute and deliver on its...

4 hours, 43 minutes ago

2 min read